The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Journal of Sleep Research · 2023-12 · 32 (6)
DOI: 10.1111/jsr.14035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Sleep Research, online erschienen am 28.11.2023. Verfasst von Dieter Riemann und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Psychology and Psychophysiology, Centre for Mental Health (Department), Medical Center - University of Freiburg, Faculty of Me…. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Melatonin. Die Arbeit wurde bisher 856-mal zitiert (Crossref) und nennt 271 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Progress in the field of insomnia since 2017 necessitated this update of the European Insomnia Guideline. Recommendations for the diagnostic procedure for insomnia and its comorbidities are: clinical interview (encompassing sleep and medical history); the use of sleep questionnaires and diaries (and physical examination and additional measures where indicated) (A). Actigraphy is not recommended for the routine evaluation of insomnia (C), but may be useful for differential‐diagnostic purposes (A). Polysomnography should be used to evaluate other sleep disorders if suspected (i.e. periodic limb movement disorder, sleep‐related breathing disorders, etc.), treatment‐resistant insomnia (A) and for other indications (B). Cognitive‐behavioural therapy for insomnia is recommended as the first‐line treatment for chronic insomnia in adults of any age (including patients with comorbidities), either applied in‐person or digitally (A). When cognitive‐behavioural therapy for insomnia is not sufficiently effective, a pharmacological intervention can be offered (A). Benzodiazepines (A), benzodiazepine receptor agonists (A), daridorexant (A) and low‐dose sedating antidepressants (B) can be used for the short‐term treatment of insomnia (≤ 4 weeks). Longer‐term treatment with these substances may be initiated in some cases, considering advantages and disadvantages (B). Orexin receptor antagonists can be used for periods of up to 3 months or longer in some cases (A). Prolonged‐release melatonin can be used for up to 3 months in patients ≥ 55 years (B). Antihistaminergic drugs, antipsychotics, fast‐release melatonin, ramelteon and phytotherapeutics are not recommended for insomnia treatment (A). Light therapy and exercise interventions may be useful as adjunct therapies to cognitive‐behavioural therapy for insomnia (B).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Psychology and Psychophysiology, Centre for Mental Health (Department), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neuroscience at the University of Oxford, Oxford, UK.
- Université de Bordeaux, Bordeaux, France.
- Reykjavik University Sleep Institute, School of Technology, Reykjavik University, Reykjavik, Iceland.
- Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.
ORCID-Profile: Dieter Riemann, Colin A Espie, Erna Sif Arnardottir, Chiara Baglioni, Leja Dolenc Groselj, Jason G Ellis, Pierre A Geoffroy, Karolina Janku, Markus Jansson-Fröjmark, Susanna Jernelöv, Samson Khachatryan, Lukas Krone, Jaap Lancee, Damien Leger, Daniel Ruivo Marques, Christoph Nissen, Laura Palagini, Dirk Pevernagie, Tamar Shochat, Eus Van Someren, Annemieke van Straten, Kai Spiegelhalder
Zitieren
APA
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., Dolenc Groselj, L., Ellis, J. G., Garcia-Borreguero, D., Geoffroy, P. A., Gjerstad, M., Gonçalves, M., Hertenstein, E., Hoedlmoser, K., Hion, T., …, & Spiegelhalder, K. (2023). The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research, 32(6). https://doi.org/10.1111/jsr.14035
Vancouver
Riemann D, Espie CA, Altena E, Arnardottir ES, Baglioni C, Bassetti CLA, et al. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research. 2023;32(6). doi:10.1111/jsr.14035
BibTeX
@article{Riemann2023,
author = {Riemann, Dieter and Espie, Colin A and Altena, Ellemarije and Arnardottir, Erna Sif and Baglioni, Chiara and Bassetti, Claudio L A and Bastien, Celyne and Berzina, Natalija and Bjorvatn, Bjørn and Dikeos, Dimitris and Dolenc Groselj, Leja and Ellis, Jason G and Garcia-Borreguero, Diego and Geoffroy, Pierre A and Gjerstad, Michaela and Gonçalves, Marta and Hertenstein, Elisabeth and Hoedlmoser, Kerstin and Hion, Tuuliki and Holzinger, Brigitte and Janku, Karolina and Jansson-Fröjmark, Markus and Järnefelt, Heli and Jernelöv, Susanna and Jennum, Poul Jørgen and Khachatryan, Samson and Krone, Lukas and Kyle, Simon D and Lancee, Jaap and Leger, Damien and Lupusor, Adrian and Marques, Daniel Ruivo and Nissen, Christoph and Palagini, Laura and Paunio, Tiina and Perogamvros, Lampros and Pevernagie, Dirk and Schabus, Manuel and Shochat, Tamar and Szentkiralyi, Andras and Van Someren, Eus and van Straten, Annemieke and Wichniak, Adam and Verbraecken, Johan and Spiegelhalder, Kai},
title = {The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023},
journal = {Journal of Sleep Research},
year = {2023},
volume = {32},
number = {6},
doi = {10.1111/jsr.14035}
}
EUVIMED